Business Context and Reporting Period
This Form 8-K filing by Aquestive Therapeutics, Inc. (AQST) reports a material event occurring on December 30, 2022. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Warren, NJ. Its common stock trades on the Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary material event is the receipt of a notice from The Nasdaq Stock Market indicating non-compliance with Listing Rule 5450(a)(1). The Company's common stock minimum bid price has remained below $1.00 per share for 30 consecutive business days. This notification has no immediate effect on the listing or trading of the stock.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has a 180-calendar day grace period, ending June 28, 2023, to regain compliance.
- Remediation Requirements: To comply, the minimum bid price must meet or exceed $1.00 per share for at least 10 consecutive business days within the grace period.
- Alternative Options: If compliance is not met by June 28, 2023, the Company may transfer to The Nasdaq Capital Market to access an additional 180-day compliance period, subject to meeting other listing standards (excluding the bid price requirement).
- Management Action: The Company intends to monitor the closing bid price and may consider a reverse stock split to regain compliance.
- Risks: There is no assurance the Company will regain compliance. Failure to do so by the end of the applicable compliance period will result in delisting. The Company retains the right to appeal a delisting determination to a hearings panel.
Investor Verification Checklist
- Verify the current trading price of AQST to assess the likelihood of meeting the $1.00 threshold within the grace period.
- Monitor future filings for announcements regarding a potential reverse stock split.
- Review the Company's cash position in recent 10-Q or 10-K filings to determine if it has the liquidity to sustain operations if delisting occurs.
- Check for any subsequent 8-K filings regarding the transfer to The Nasdaq Capital Market or an appeal of a delisting decision.